Hannah Brendan
SEC CIK 1929422 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | Chief Business Off | 336.5K | $111.7K | — | 7 | 2022-05-19 | 2025-12-05 |
Most active insiders at QNCX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Benatti Luca | Dir | — | $173.5K |
| 2 | Hannah Brendan | COO, CCO, CBO | — | — |
| 3 | Thye Dirk | CEO, CMO, Dir | — | — |
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-08 | 2025-12-05 | QNCX | Quince Therapeutics, Inc. | Hannah Brendan | COO, CCO, CBO | M - OptEx | $0.9079 | +27.6K | 336.5K | +9% | +$25.0K |
| D | 2025-06-23 | 2025-06-18 | QNCX | Quince Therapeutics, Inc. | Hannah Brendan | COO, CCO, CBO | A - Grant | $1.20 | +37.7K | 334.3K | +13% | +$45.3K |
| M | 2024-08-21 | 2024-08-19+ | QNCX | Quince Therapeutics, Inc. | Hannah Brendan | Chief BUSINESS Off. AND COO | P - Purchase | $0.6209 | +38.9K | 265.7K | +17% | +$24.2K |
| D | 2024-06-05 | 2024-06-04 | QNCX | Quince Therapeutics, Inc. | Hannah Brendan | Chief BUSINESS Off. AND COO | M - OptEx | $0.55 | +56.1K | 257.6K | +28% | +$30.8K |
| 2023-08-09 | 2023-08-08 | QNCX | Quince Therapeutics, Inc. | Hannah Brendan | Chief Business Off | P - Purchase | $1.22 | +71.8K | 201.6K | +55% | +$87.5K | |
| A | 2022-05-27 | 2022-05-19 | QNCX | Quince Therapeutics, Inc. | Hannah Brendan | Chief Business Off | A - Grant | $0.00 | +113.6K | 129.8K | +700% | $0 |
| D | 2022-05-23 | 2022-05-19 | QNCX | Quince Therapeutics, Inc. | Hannah Brendan | Chief Business Off | A - Grant | — | +16.2K | 16.2K | New | — |
Purchase Sale Sale after option exercise All abbreviations